Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › Lung Cancer Immune Microenvironment May Vary Within Tumor, Complicating TMB-Based Predictions

Lung Cancer Immune Microenvironment May Vary Within Tumor, Complicating TMB-Based Predictions

Dec 18, 2018
|
staff reporter

NEW YORK (GenomeWeb) – New research suggests that a single biopsy may not be sufficient for profiling immune cell activity in the microenvironment of non-small cell lung carcinoma (NSCLC) tumors. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
09
Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

Nov
17
Featured Webinar

Spatial Expression Analyses Elucidates Mechanisms of circRNAs in Cancer

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.

Nov
23
Featured Webinar

Liquid Biopsy to Understand Resistance Mechanisms in Non-Small Cell Lung Cancer

Sponsored by
Inivata

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment. 

What's Popular?

In Sequencing

  1. SickKids' 'Rigorous' Molecular Analysis IDs Targetable Alterations, Cancer Susceptibility Mutations

    Premium

  2. Caris Life Sciences Raises $310M Through Equity, Debt Financing

  3. Maverick Therapeutics to Use Inivata's Liquid Biopsy Assay in Phase I/II Clinical Study

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.